Trial Profile

Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ethyl eicosapentaenoic acid (Primary)
Indications Coronary artery disease
Focus Therapeutic Use
Acronyms RESPECT-EPA

Most Recent Events

17 Nov 2022 New trial record
07 Nov 2022 Results (n=2460) assessing the effect of EPA on cardiovascular events in combination with statins and it has also addressed a prognostic implication of EPA/AA ratio for patients with coronary artery disease, presented at the American Heart Association Scientific Sessions 2022.
07 Nov 2022 Results published in the Amarin Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com